The initial concept underlying these studies was that HBD2 could be employed as a direct antiprotease to prevent or treat S. aureus V8-mediated skin damage, with additional direct selective microbicidal properties that might help to address skin dysbiosis in individuals with AD. This evidence concerns the gene DEFB4A and Alzheimer disease.